Result of AGM

Dr. Martens PLC

15 July 2026

 

15 July 2026

DR. MARTENS PLC

RESULT OF ANNUAL GENERAL MEETING

15 JULY 2026

The Company announces the results of voting at its Annual General Meeting held earlier today and confirms that all resolutions were duly passed on a poll with majorities as set out below.

Resolutions 1 to 16 were proposed as Ordinary Resolutions and resolutions 17 to 20 as Special Resolutions.

Resolution		Votes For (note 1)	%	Votes Against (note 1)	%	Votes Total	Votes Withheld (note 2)	% Voting Capital Instructed
01	Receive the 2026 Annual Report and Accounts	796,957,114	99.99	40,567	0.01	796,997,681	656,372	82.34%
02	Approve the Directors' Remuneration Report	796,937,723	99.97	201,393	0.03	797,139,116	514,937	82.35%
03	Approve the Final Dividend	797,096,340	99.99	48,759	0.01	797,145,099	508,954	82.35%
04	Re-elect Paul Mason	680,070,438	85.31	117,069,614	14.69	797,140,052	514,001	82.35%
05	Re-elect Ije Nwokorie	721,173,072	90.47	75,967,312	9.53	797,140,384	513,669	82.35%
06	Re-elect Giles Wilson	721,165,856	90.47	75,974,525	9.53	797,140,381	513,672	82.35%
07	Re-elect Robyn Perriss	775,726,615	97.31	21,415,207	2.69	797,141,822	512,231	82.35%
08	Re-elect Andrew Harrison	782,771,472	98.20	14,368,942	1.80	797,140,414	513,639	82.35%
09	Re-elect Ian Rogers	775,355,475	97.27	21,786,386	2.73	797,141,861	512,192	82.35%
10	Re-elect Robert Hanson	782,337,763	98.14	14,802,553	1.86	797,140,316	513,737	82.35%
11	Re-elect Tara Alhadeff	701,224,174	87.97	95,917,854	12.03	797,142,028	512,025	82.35%
12	Re-elect Benoit Vauchy	720,136,984	90.34	77,004,838	9.66	797,141,822	512,231	82.35%
13	Re-appoint PricewaterhouseCoopers LLP as auditor	797,059,524	99.99	65,737	0.01	797,125,261	528,792	82.35%
14	Authorise the Audit & Risk Committee to determine the Auditor's remuneration	797,072,443	99.99	68,433	0.01	797,140,876	513,177	82.35%
15	Authorise the Company and its subsidiaries to make political donations	796,818,677	99.96	327,853	0.04	797,146,530	507,523	82.35%
16	Authorise allotment of shares	790,698,389	99.20	6,387,690	0.80	797,086,079	567,974	82.35%
17	Authorise general disapplication of pre-emption rights*	754,687,652	94.68	42,387,365	5.32	797,075,017	579,036	82.35%
18	Authorise additional disapplication of pre-emption rights*	754,417,184	94.65	42,660,766	5.35	797,077,950	576,103	82.35%
19	Authorise purchase of own shares*	787,550,622	98.81	9,481,431	1.19	797,032,053	622,000	82.34%
20	Authorise calling of general meetings on 14 days' notice*	795,512,977	99.80	1,628,457	0.20	797,141,434	512,619	82.35%

*Special Resolution

The votes of independent shareholders on the resolutions concerning the election or re-election of the Independent Non-Executive Directors are set out below:

Resolution		Votes For	%	Votes Against	%	Votes Total	Votes Withheld	% Independent Capital Instructed
07	Re-elect Robyn Perriss	405,784,175	94.99	21,415,207	5.01	427,199,382	512,231	71.43%
08	Re-elect Andrew Harrison	412,829,032	96.64	14,368,942	3.36	427,197,974	513,639	71.43%
09	Re-elect Ian Rogers	405,413,035	94.90	21,786,386	5.10	427,199,421	512,192	71.43%
10	Re-elect Robert Hanson	412,395,323	96.53	14,802,553	3.47	427,197,876	513,737	71.43%

Notes:

1.     Votes "For" and "Against" are expressed as a percentage of votes received.

2.     A "Vote withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.

3.     As at 6.30pm on 14 July 2026 the Company had a total of 967,969,739 ordinary shares with voting rights in issue. The total independent voting capital, used to calculate the votes of independent shareholders on resolutions 7 to 10, was 598,027,299.

4.     In accordance with Listing Rule 6.4.2(R), copies of the resolutions passed as special business will shortly be available for inspection on the National Storage Mechanism at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

Enquiries

Company Secretariat

Paul Rolling, Head of Secretariat                                                                                           [phone]

Investors and analysts                                                                       

Bethany Barnes, Director of Investor Relations                                                                     [phone]

and Corporate Communications                                                                                             [e-mail]

Press                                                                                                                                                    

Sodali & Co                                                                           

Ludo Baynham-Herd                                                                                                                          

Rob Greening                                                                                                                                      
                                                                                                                                                    [e-mail]

                                                                                                                                                     [phone]

About Dr. Martens

Dr. Martens is an iconic British footwear brand founded in Northamptonshire, England. Its first silhouette, the 1460 boot - named after the date it was produced - rolled off the production line on 1st April 1960. Originally chosen by workers for their air-cushioned comfort and durability, "Docs" or "DM's" were later adopted by musicians and subcultural pioneers who took them from the street to the global stage.

Over six decades later, Dr. Martens operates in more than 60 countries and employs around 3,600 people. The company continues to honour the brand's heritage through its 'Made in England' footwear, manufactured at its original Northamptonshire factory, while meeting global demand from multiple high-quality production sites across Asia. All our products are made with an unwavering commitment to craft, combined with innovative techniques.

A brand built to put a bounce in the step of those who stand out from the crowd, Dr. Martens is available through Direct-to-Consumer (Retail and Ecommerce) and Wholesale channels. The brand's collections range from its Original silhouettes - The Icons such as the 1460 boot, 1461 shoe, 2976 Chelsea boot, and Adrian loafer - to modern franchises like the Zebzag, Buzz, and Lowell. The lineup also includes an extensive range of sandals, a dedicated Kids collection, and a curated selection of bags, small leather goods, and accessories.

Every Dr. Martens product reflects craftsmanship, heritage, timeless style, comfort, and versatility. Having transcended generations, the brand stays as relevant today as it was at its inception. Its signature yellow welt stitching, grooved sole edges, and scripted "With Bouncing Soles" heel loops remain iconic symbols recognised around the world.

Dr. Martens plc (DOCS.L) is listed on the main market of the London Stock Exchange and is a constituent of the FTSE 250 index.

For more information, visit www.drmartens.com or www.drmartensplc.com

 

END